

September 12, 2023

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Please refer to the disclosure made by the Company on July 3, 2023 regarding acquisition of certain marketing and manufacturing related authorisations.

Further updates regarding the aforesaid disclosure are attached as '**Annexure - I**' to this disclosure.

This is for your information and record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Encl.: As above

Annexure - I

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) Name of the target entity, details in brief such as size, turnover etc.;	Acquisition of 15 specified Marketing and Manufacturing related authorizations of branded products and related Brand Trademarks from Viatris Inc./ Pfizer Inc. for Indonesia market.
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length";	No.
c) Industry to which the entity being acquired belongs;	Pharmaceutical Formulations
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Provides an excellent entry platform into fast growing Pharmaceutical market of Indonesia.
e) Brief details of any governmental or regulatory approvals required for the acquisition;	We expect general approvals of routine nature to complete the transaction.
f) Indicative time period for completion of the acquisition;	By 28 February 2024
g) Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
h) Cost of acquisition or the price at which the shares are acquired;	Cash consideration of USD 48 mn
i) Percentage of shareholding / control acquired and / or number of shares acquired;	Not applicable
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Sales Revenue generated from specified MAs in Indonesian market is mentioned below for each of calendar years: 2022: USD 30.5 mn 2021: USD 28.3 mn 2020: USD 25.1 mn

AUROBINDO PHARMA LIMITED
www.aurobindo.com

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S, INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com